Test Price
8,500 AED✅ Home Collection Available
Can Assist Breast Test in UAE | 8500 AED | 2026 DHA Guidelines
تحليل Can Assist Breast Test في الإمارات | 8500 درهم | معتمد من هيئة الصحة بدبي
Executive Summary / ملخص تنفيذي
اختبار Can Assist Breast هو فحص نسيجي مناعي متطور يعتمد على الكيمياء المناعية لتحديد مدى خطورة عودة سرطان الثدي إيجابي مستقبلات الإستروجين والبروجسترون وسلبي HER2، معتمد من هيئة الصحة بدبي وموافق لأحدث معايير الجودة ISO 9001:2015.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Overview
Can Assist Breast Test is a prognostic immunohistochemistry assay that stratifies 10-year recurrence risk for early-stage, ER‑positive, PR‑positive, HER2‑negative breast cancer patients. يُستخدم هذا الفحص لتوجيه قرارات العلاج الكيميائي المساعد وتجنب العلاجات غير الضرورية.
| Feature | Can Assist Breast Test (Our Service) | Standard Prognostic Panel |
|---|---|---|
| Precision | Machine‑learning algorithm with IHC quantification | Manual IHC scoring, higher inter‑observer variability |
| Methodology | Immunohistochemistry (IHC) + Fragment & STR Analysis | IHC alone without integrative algorithmic interpretation |
| Turnaround | 15 working days post FFPE block receipt | Often 20–25 working days |
Physician Insight & Safety Protocol
Dr. PRABHAKAR REDDY (DHA: 61713011) emphasizes: “This test is a powerful decision‑support tool, yet it must always be correlated with full clinical evaluation and multidisciplinary tumour board discussion. Patient empowerment through accurate molecular profiling is our collective responsibility.”
Medication Warning:
Do not discontinue prescribed medication without consulting your doctor.
Exclusion Criteria & ER Red Flags
- Must be histologically confirmed invasive breast carcinoma, ER (+), PR (+), HER2 (−).
- Not validated for HER2‑positive or triple‑negative disease.
- Insufficient tumour content in FFPE block (<30% tumour cells) may yield inconclusive results.
- If you experience new breast lump, skin dimpling, persistent bone pain, or severe shortness of breath, seek immediate medical attention – these may indicate progression requiring urgent clinical review.
Patient FAQ & Clinical Guidance
What is the Can Assist Breast test and how is it performed?
The Can Assist Breast test is a prognostic immunohistochemistry assay that predicts 10‑year recurrence risk in early‑stage ER+ PR+ HER2‑negative breast cancer patients. In the laboratory, a paraffin‑embedded tumour tissue block is sectioned and stained with specific antibodies; the results are analysed by a proprietary algorithm that integrates multiple protein expression patterns into a single risk score. This score aids oncologists in deciding whether adjuvant chemotherapy may be safely omitted.
اختبار Can Assist Breast هو فحص نسيجي مناعي يُجرى على عينة نسيج الورم المضمنة في البارافين لتحديد خطورة عودة الورم خلال 10 سنوات لدى مريضات سرطان الثدي إيجابي ER و PR وسلبي HER2، حيث تُصبغ العينة ويُحلل التعبير البروتيني بواسطة خوارزمية متقدمة لتوجيه العلاج.
How do I prepare for the and what documents are required?
No patient preparation is required beyond the mandatory submission of a duly filled Can Assist Breast Requisition Form (Form 41) alongside the FFPE tissue block. You must ensure the referring oncologist completes the form with accurate clinical and pathological data. Home collection service is available from 8 AM to 11 PM; our phlebotomy team will retrieve the block directly from your pathology lab or hospital, maintaining cold‑chain integrity throughout.
لا حاجة لتحضير المريض، لكن يلزم تقديم نموذج الطلب الإلزامي (استمارة 41) مكتملة البيانات مع كتلة النسيج المضمنة بالبارافين، ويمكن ترتيب خدمة الاستلام المنزلي في أي وقت بين 8 صباحًا و11 مساءً مع الحفاظ على سلسلة التبريد.
When will I receive my results and will they be explained to me?
A final validated report is delivered within 15 working days, and you will receive a telephonic clinical guidance session after report issuance. Results include a risk category (low or high) and a personalised recurrence probability. Our DHA‑licensed specialists will interpret the findings and answer your questions, ensuring you fully understand the implications for your treatment plan.
تصدر النتائج خلال 15 يوم عمل ويتبعها جلسة إرشاد سريري هاتفية تشرح فئة الخطورة واحتمالية التكرار، مع إمكانية مناقشة النتائج مع أخصائيينا المرخصين من هيئة الصحة بدبي.
Regulatory Compliance: Adheres to Federal Decree‑Law No. 41 of 2024 (Art. 87) on diagnostic validity, UAE PDPL data privacy, and CDS Law 2026 provisions for patient safety. Laboratory DHA License: 9834453 | ISO 9001:2015 Cert: INT/EGQ/2509DA/3139.
© 2026 All rights reserved. Last reviewed by Dr. PRABHAKAR REDDY, DHA 61713011.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians